NASDAQ$MBRX
Moleculin Biotech Inc · Q4 2020 earnings
Q4 2020 earnings · · Investor relations
Briefing
Moleculin reported its financial results for the year ended December 31, 2020 and provided a business update.
Moleculin Biotech, Inc. reported a net loss of $17.4 million for the year ended December 31, 2020. The company's R&D expenses increased to $12.8 million, and G&A expenses rose to $6.8 million. The company believes that its cash resources as of December 31, 2020, along with the additional funding received subsequent to year-end, will be sufficient to meet its projected operating requirements through at least the year 2023.
- Raised gross proceeds of approximately $81 million through registered equity offering and ATM program in 1Q21, providing runway into 2025 based on current R&D spending levels.
- Received $1.5 million grant to fund a Phase 1b/2 clinical trial for Annamycin for the treatment of soft tissue sarcoma lung metastases in Europe.
- Reported positive interim results in Emory University pediatric brain tumor Phase 1 clinical trial for WP1066.
- Observed positive in vitro results demonstrating the antiviral activity of WP1096 and WP1097 against SARS-CoV-2, HIV, Zika, and Dengue Fever.
Headline financials
Revenue & EPS history
Moleculin · Revenue · Quarterly
$0
Forward guidance
Moleculin anticipates several milestones in 2021, including the potential for 8 clinical trials and further development of their drug candidates.
Tailwinds
- Establishing a recommended Phase 2 Dose for Annamycin in 2021.
- Timing of the commencement and progress of the clinical trials conducted by Moleculin and by third parties.
- The ability of Moleculin to find a collaborative partner to support a Phase 2 clinical study of WP1220 in CTCL in 2021.
- The ability to file for W1122 an IND application or its equivalent for either cancer-related or virus-related clinical trials in the first half of 2021.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q4 2020
-1.3%
Avg return
Earnings day
-1.3%
Avg return
5 days after
-5.3%
Avg return
30 days after
33%
13 / 40 earnings
Positive
+28.1%
Q4 2019
Best reaction
-20.8%
Q4 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | — | — | — | |
| Q1 2026 | +2.8% | +9.8% | — | |
| Q3 2025 | -4.4% | -3.5% | -56.1% | |
| Q2 2025 | -4.0% | -11.7% | -46.1% | |
| Q1 2025 | -8.2% | -1.3% | -35.3% | |
| Q4 2024 | -2.8% | -3.7% | -12.8% | |
| Q3 2024 | +3.5% | +6.3% | +3.9% | |
| Q2 2024 | -5.1% | +2.1% | +3.4% | |
| Q1 2024 | +1.9% | +6.7% | -9.2% | |
| Q4 2023 | -20.8% | -16.4% | -29.9% | |
| Q3 2023 | +1.9% | +9.3% | -2.4% | |
| Q2 2023 | -1.3% | -7.5% | -32.7% | |
| Q1 2023 | -14.4% | -21.7% | -23.1% | |
| Q4 2022 | -1.9% | -7.8% | -24.0% | |
| Q3 2022 | +5.1% | +6.1% | +48.6% | |
| Q2 2022 | +9.3% | +3.7% | -12.3% | |
| Q1 2022 | +1.6% | +9.0% | +23.0% | |
| Q4 2021 | -4.4% | -1.7% | +1.1% | |
| Q3 2021 | +0.0% | -6.5% | -5.7% | |
| Q2 2021 | -3.3% | -11.1% | -0.3% | |
| Q1 2021 | -3.8% | -2.6% | +13.2% | |
| Q4 2020 | -1.5% | -6.6% | -99.8% | |
| Q3 2020 | +2.9% | +8.5% | +14.1% | |
| Q2 2020 | -7.4% | -5.6% | -29.0% | |
| Q1 2020 | +0.0% | +0.0% | +11.2% | |
| Q4 2019 | +28.1% | +27.9% | +155.9% | |
| Q3 2019 | +0.9% | -0.9% | -4.7% | |
| Q2 2019 | +6.5% | +10.2% | +13.0% | |
| Q1 2019 | -0.8% | -5.7% | -4.9% | |
| Q4 2018 | +3.8% | -1.5% | -0.8% | |
| Q3 2018 | -3.1% | +6.1% | -3.8% | |
| Q2 2018 | +0.0% | -1.2% | +0.0% | |
| Q1 2018 | -0.6% | -0.6% | +12.1% | |
| Q4 2017 | -3.2% | -1.1% | -0.5% | |
| Q3 2017 | -0.4% | +3.7% | +5.6% | |
| Q2 2017 | -7.7% | -11.8% | -3.7% | |
| Q1 2017 | -4.7% | -4.9% | +0.0% | |
| Q4 2016 | -12.8% | -28.2% | -27.4% | |
| Q3 2016 | -2.4% | +1.7% | -50.5% | |
| Q2 2016 | -1.6% | -6.7% | -1.0% | |
| Q1 2016 | +2.3% | +5.4% | +5.2% | |
| Q3 2015 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro